Suppr超能文献

用T细胞生长因子(TCGF)培养的鼠淋巴细胞在体外的天然细胞介导细胞毒性及在体内对肿瘤生长的抑制作用。

Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF).

作者信息

Kedar E, Ikejiri B L, Gorelik E, Herbermann R B

出版信息

Cancer Immunol Immunother. 1982;13(1):14-23. doi: 10.1007/BF00200195.

Abstract

Lymphoid cells obtained from the spleen, thymus, bone marrow, peripheral blood, and peritoneal exudate of normal mice (BALB/c, BALB/c nude, C57BL/6, C3H) and from spleens of mice bearing a transplantable lung carcinoma or primary mammary carcinoma were expanded in culture for 1-9 months, with an increase in cell number of 10(5)- to 10(6)-fold per month, in crude or lectin-depleted medium containing T cell growth factor (TCGF). All these cultured lymphoid cell (CLC) lines exhibited strong cytotoxic activity in vitro (assessed by 51Cr-release assays) toward a variety of freshly harvested and cultured syngeneic, allogeneic, and xenogeneic tumor target cells, both lymphoid and solid (including metastatic growths) in origin. Extensive killing was observed against tumor targets that were resistant to lysis by natural killer (NK) cells as well as to NK-sensitive tumor lines. Low levels of cytotoxic reactivity were also demonstrated against fresh and cultured normal lymphoid cells. The CLC had some characteristics of NK cells but also expressed some typical T cell markers. In local Winn-type neutralization assays, CLC delayed or completely inhibited the growth of lymphomas and carcinomas in syngeneic and allogeneic recipients. In mice with metastatic growth of a second-generation transplant of mammary carcinoma, CLC were shown to have some therapeutic effect when administered IV 1 day after cyclophosphamide. No significant beneficial action of IV administered CLC was observed in the absence of chemotherapy in mice implanted with a lung carcinoma. The possibilities of employing TCGF-propagated cytotoxic effector cells in adoptive immunotherapy of human malignancies are discussed.

摘要

从正常小鼠(BALB/c、BALB/c裸鼠、C57BL/6、C3H)的脾脏、胸腺、骨髓、外周血和腹腔渗出液以及患有可移植肺癌或原发性乳腺癌的小鼠脾脏中获取的淋巴细胞,在含有T细胞生长因子(TCGF)的粗制或去除凝集素的培养基中培养1 - 9个月,细胞数量每月增加10⁵至10⁶倍。所有这些培养的淋巴细胞(CLC)系在体外(通过⁵¹Cr释放试验评估)对多种新鲜收获和培养的同基因、异基因和异种肿瘤靶细胞表现出强烈的细胞毒性活性,这些靶细胞包括起源于淋巴样和实体(包括转移性生长物)的细胞。观察到对天然杀伤(NK)细胞裂解有抗性以及对NK敏感的肿瘤细胞系的肿瘤靶标有广泛的杀伤作用。对新鲜和培养的正常淋巴细胞也表现出低水平的细胞毒性反应。CLC具有一些NK细胞的特征,但也表达一些典型的T细胞标志物。在局部Winn型中和试验中,CLC延迟或完全抑制了同基因和异基因受体中淋巴瘤和癌的生长。在患有第二代移植性乳腺癌转移性生长的小鼠中,在环磷酰胺给药后1天静脉注射CLC显示有一定治疗效果。在植入肺癌的小鼠中,在无化疗的情况下静脉注射CLC未观察到明显的有益作用。讨论了在人类恶性肿瘤的过继免疫治疗中应用TCGF扩增的细胞毒性效应细胞的可能性。

相似文献

引用本文的文献

3
Vaccination for melanoma.黑色素瘤疫苗接种
Curr Oncol Rep. 2000 Jul;2(4):292-9. doi: 10.1007/s11912-000-0021-0.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验